Integrated Evaluation of Survival, Surgical Conversion, and Toxicity for Induction Therapy in Initially Unresectable Colorectal Liver Metastases: An Individual Patient Data Network Meta-analysis.

Ann Surg OncolJul 16, 2026 (epub)
Clinical ResearchOncology (Medical)General SurgeryOpen access

Guilin Nie, Xinming Li, Yaoqun Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the efficacy of induction therapies for initially unresectable colorectal cancer liver metastases (CRLM) using individual patient data from seven randomized controlled trials involving 1368 patients. Bevacizumab plus triplet chemotherapy was found to have the highest probability of improving R0-1 resection rate and prolonging progression-free survival (PFS) at 0.99, although it was associated with greater toxicity.

Key findings

  • Bevacizumab + triplet-chemotherapy had a 0.99 probability of improving R0-1 resection rate.
  • Bevacizumab + triplet-chemotherapy also had a 0.99 probability of prolonging progression-free survival.
  • Cetuximab + doublet-chemotherapy outperformed chemotherapy in prolonging PFS for KRAS/BRAF wild-type tumors.
  • Bevacizumab + doublet-chemotherapy showed the highest Topsis score of 0.67 for a balanced benefit-risk profile.

Why it matters

Understanding the comparative efficacy and safety of induction therapies for unresectable CRLM is crucial for optimizing treatment strategies and improving patient outcomes, particularly regarding surgical conversion rates and managing adverse events.

Source

PubMed · PMID 42463606Free full text on PubMed Central

Published in Ann Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.